Accueil/Actions/VERU

VERU

USD

Veru Inc. Common Stock

$0.653-0.007 (-1.061%)

Prix en Temps Réel

Healthcare

Biotechnologie

États-Unis

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché

Fondamentaux de l'Entreprise

Statistiques de Trading

Métriques de Marché

Ouverture

$0.660

Haut

$0.685

Bas

$0.612

Volume

1.69M

Fondamentaux de l'Entreprise

Capitalisation Boursière

95.7M

Industrie

Biotechnologie

Pays

United States

Statistiques de Trading

Volume Moyen

2.33M

Bourse

NCM

Devise

USD

Intervalle sur 52 Semaines

Bas $0.45Actuel $0.653Haut $1.42

Actualités Connexes

28 mai 2025 · 10:30

GlobeNewswire

Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone

--Phase 2b QUALITY clinical study topline safety data shows that the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone-- --Based on Phase 2b QUALITY trial efficacy and

Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone

8 mai 2025 · 10:30

GlobeNewswire

Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress

--Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second quarter of